AGEN, en pre, +7,5%...a ver si no afloja..
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results (NCT03860272)
- Seventeen objective responses reported across nine cancers
- Evidence of monotherapy activity, with four cases of confirmed objective response
- Objective responses noted in treatment refractory, poorly immunogenic tumors including microsatellite stable (MSS) colorectal cancer, ovarian cancer, MSS endometrial cancer, and melanoma; as well as responses in tumors not previously reported including pancreatic cancer, cervical cancer, visceral angiosarcoma, non-small cell lung cancer, and leiomyosarcoma
- No cases of hypophysitis, pneumonitis, or high-grade hepatitis
- Phase 2/3 trials to be initiated in colorectal and gynecological cancers
.....................................................................................................................................
Pendiente del resto de news del SITC...
IMV
Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer
AVEO
Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3
CTMX
Preclinical data for a conditionally activated interferon alpha-2b (IFN-a2b)
ONCS
Clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC 2021 Annual Meeting. Specifically, the KEYNOTE-695 clinical trial enrolled metastatic melanoma patients that are refractory to Immune Checkpoint Blockade, non-responders as defined by the Society of Immunotherapy of Cancer (SITC) recommendations
Un saludo y muchos aciertos